M. Callahan

Oncology · 2012–2020

A researcher in the Science corpus: 15 papers; trusts 1 researcher and is trusted by 2 researchers here, as inferred from the citation graph.

Subfields

• Oncology — 213 citations into it; #1,276 of 1,698 by trust here, #78 by citations

Whom M. Callahan trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

1. J. Wolchok
2. F. Hodi

Who trusts M. Callahan overall

1. Padmanee Sharma

Papers from M. Callahan's perspective

Ordered by how strongly the researchers M. Callahan trusts endorse each paper. Same corpus, a different order for every researcher.

1. Improved Survival with Ipilimumab in Patients with Metastatic Melanoma (New England Journal of Medicine)
2. Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer (New England Journal of Medicine)
3. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. (The Lancet)
4. Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria (Clinical Cancer Research)
5. PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma (New England Journal of Medicine)
6. Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. (Science)
7. Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma (New England Journal of Medicine)
8. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised,… (The Lancet Oncology)
9. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single arm, phase 2 trial (The Lancet)
10. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients (Nature)

Their papers

• Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET (2012) — 3,522 citations
• Combined Nivolumab and Ipilimumab or Monotherapy in Previously Untreated Melanoma (2015) — 4,132 citations
• Hepatotoxicity with combination of vemurafenib and ipilimumab. (2013) — 697 citations
• Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis (2016) — 915 citations
• Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center. (2015) — 926 citations
• Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma (2017) — 3,400 citations
• Immune-related adverse events of checkpoint inhibitors (2020) — 992 citations
• Tumor Mutation Burden and Efficacy of Nivolumab Monotherapy and in Combination With Ipilimumab in Small Cell Lung Cancer (2018) — 764 citations
• Genomic features of response to combination immunotherapy in patients with advanced non-small cell lung cancer (2018) — 921 citations
• OncoKB: A Precision Oncology Knowledge Base (2017) — 2,318 citations
• Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy. (2017) — 1,030 citations
• Immune Checkpoint Blockade in Cancer Therapy. (2015) — 2,369 citations
• Pituitary Expression of CTLA-4 Mediates Hypophysitis Secondary to Administration of CTLA-4 Blocking Antibody (2014) — 651 citations
• Safety and clinical activity of combined PD-1 (nivolumab) and CTLA-4 (ipilimumab) blockade in advanced melanoma patients (2013) — 3,871 citations
• Immunologic Correlates of the Abscopal Effect in a Patient with Melanoma (2012) — 1,966 citations